AR080811A1 - Analogos para el tratamiento o prevencion de infecciones por flavivirus - Google Patents
Analogos para el tratamiento o prevencion de infecciones por flavivirusInfo
- Publication number
- AR080811A1 AR080811A1 ARP110101005A ARP110101005A AR080811A1 AR 080811 A1 AR080811 A1 AR 080811A1 AR P110101005 A ARP110101005 A AR P110101005A AR P110101005 A ARP110101005 A AR P110101005A AR 080811 A1 AR080811 A1 AR 080811A1
- Authority
- AR
- Argentina
- Prior art keywords
- nrarb
- unsubstituted
- substituted
- ora
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto de formula (1) o una sal farmacéuticamente aceptable del mismo, en la que cada A es independientemente arilo C6-14, heterociclo de 4-12 miembros, cicloalquilo C3-10 o heteroarilo de 5-12 miembros; cada uno de B y B' está independientemente ausente, es alquilo C1-6, alquenilo C2-6 o alquinilo C2-6; cada uno de C y C' es independientemente un heterociclo de 4-7 miembros; D y D' son independientemente un anillo heterocíclico de 5,6 miembros que comprende al menos un átomo de nitrogeno en el anillo de cinco miembros, en el que el punto de union a B o B' está en el anillo de seis miembros, y en el que ni D ni D' son bencimidazol; R1 es halogeno, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hidroxilo, nitro, azido, ciano, -S(O)0-3Ra, SO2NRaRb, -NRbSO2Ra, -NRbSO2NRaRb, -P(=O)ORaORb, alquilo C1-6 que está sin sustituir o sustituido una o más veces con R10, alquenilo C2-6 que está sin sustituir o sustituido una o más veces con R10, alquinilo C2-6 que está sin sustituir o sustituido una o más veces con R10, o dos apariciones cualesquiera de R1 pueden tomarse juntos con los átomos a los que están unidas para formar un cicloalquilo 5-7 que está sin sustituir o sustituido una o más veces con R11 o un heterociclo de 5-7 miembros que está sin sustituir o sustituido una o más veces con R12, cada uno de Ra-Rd es independientemente H, alquilo C1-12, alquenilo C2-12, alquinilo C2-12, arilo C6-12, aralquilo C7-16, heteroarilo de 5-12 miembros, heteroaralquilo de 6-18 miembros, heterociclo de 3-12 miembros o heterocicloalquilo de 4-18 miembros; cada uno de R2 y R2' es independientemente halogeno, alquilo C1-10, alquilo C1-6 halogenado, -(CH2)1-6OH, -ORa, -C(=O)ORa, -NRaRb, -NRbC(=O)Ra, -C(O)NRaRb, -S(O)0-3Ra, arilo C6-12, heterociclo de 5-12 miembros o heteroarilo de 5-12 miembros; cada uno de R3 y R3' es independientemente H, alquilo C1-6, -(CH2)1-6OH, alquenilo C2-6 o alquinilo C2-6; cada uno de R4 y R4' es independientemente halogeno, -NRaRb, -C(O)NRaRb, -(CH2)1-6OH, alquilo C1-6, alquilo C1-6 halogenado, hidroxilo, arilo C6-14 o alcoxi C1-6; en la que las dos apariciones de R4 pueden tomarse junto con los átomos a los que están unidas para formar un alquenilo C1-6 que está sin sustituir o sustituido una o más veces con R10, un cicloalquilo de 3-7 miembros que está sin sustituir o sustituido una o más veces con R11 o un heterociclo de 4-7 miembros que está sin sustituir o sustituido una o más veces con R12; en la que dos apariciones de R4' pueden tomarse junto con los átomos a los que están unidas para formar un alquenilo C1-6 que está sin sustituir o sustituido una o más veces con R10, un cicloalquilo de 3-7 miembros que está sin sustituir o sustituido una o más veces con R11 o un heterociclo de 4-7 miembros que está sin sustituir o sustituido una o más veces con R12; cada uno de X e Y es independientemente C(=O), *-C(=O)O, *-C(=O)N-R6, -S(=O)2-, o un enlace; en las que el asterisco (*) indica el punto de union al nitrogeno del anillo C o C'; cada uno de R5 y R5' es independientemente H, alquilo C1-18 que está sin sustituir o sustituido una o más veces con R10, alquenilo C2-12 que está sin sustituir o sustituido una o más veces con R10, alquinilo C2-12 que está sin sustituir o sustituido una o más veces con R10, arilo C6-14 que está sin sustituir o sustituido una o más veces con R11, aralquilo C7-16 que está sin sustituir o sustituido una o más veces con R11, heteroarilo de 5-12 miembros que está sin sustituir o sustituido una o más veces con R11, heteroaralquilo de 6-18 miembros que está sin sustituir o sustituido una o más veces con R11, heterociclo de 3-12 miembros que está sin sustituir o sustituido una o más veces con R12 o heterociclo-alquilo de 4-18 miembros que está sin sustituir o sustituido una o más veces con R12; R6 es H, alquilo C1-6 o alquilo C1-6 halogenado; cada uno de m y n es independientemente 0, 1, 2, 3 o 4; p es 0, 1, 2, 3 o 4; q es 0, 1 o 2; s es 0, 1, 2, 3 o 4; R10 es halogeno, -ORa, oxo, -NRaRb, =NO-Rc, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hidroxilo, nitro, azido, ciano, -S(O)0-3Ra, SO2NRaRb, -NRbSO2Ra, -NRbSO2NRaRb, o -P(=O)ORaORb, R11 es halogeno, -ORa, -NRaRb, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hidroxilo, nitro, azido, ciano, -S(O)0-3Ra, SO2NRaRb, -NRbSO2Ra, -NRbSO2NRaRb, o -P(=O)ORaORb, alquilo C1-12, alquenilo C2-12, alquinilo C2-12, arilo C6-12, aralquilo C7-16, heteroarilo de 5-12 miembros, heteroaralquilo de 6-18 miembros, heterociclo de 3-12 miembros o heterociclo-alquilo de 4-18 miembros; y R12 es halogeno, -ORa, oxo, -NRaRb, =NO-Rc, -C(=O)ORa, -C(O)NRaRb, -C(=O)OH, -C(=O)Ra, -C(=NORc)Ra, -C(=NRc)NRaRb, -NRdC(=O)NRaRb, -NRbC(=O)Ra, -NRdC(=NRc)NRaRb, -NRbC(=O)ORa, -OC(=O)NRaRb, -OC(=O)Ra, -OC(=O)ORa, hidroxilo, nitro, azido, ciano, -S(O)0-3Ra, SO2NRaRb, -NRbSO2Ra, -NRbSO2NRaRb, o -P(=O)ORaORb, alquilo C1-12, alquenilo C2-12, alquinilo C2-12, arilo C6-12, aralquilo C7-16, heteroarilo de 5-12 miembros, heteroaralquilo de 6-18 miembros, heterociclo de 3-12 miembros o heterociclo-alquilo de 4-18 miembros.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31699510P | 2010-03-24 | 2010-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR080811A1 true AR080811A1 (es) | 2012-05-09 |
Family
ID=44121557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110101005A AR080811A1 (es) | 2010-03-24 | 2011-03-28 | Analogos para el tratamiento o prevencion de infecciones por flavivirus |
Country Status (5)
Country | Link |
---|---|
US (1) | US20130085150A1 (es) |
EP (1) | EP2550262A1 (es) |
AR (1) | AR080811A1 (es) |
TW (1) | TW201139438A (es) |
WO (1) | WO2011119858A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2367824B1 (en) | 2008-12-23 | 2016-03-23 | AbbVie Inc. | Anti-viral derivatives of pyrimidine |
CN102245604A (zh) | 2008-12-23 | 2011-11-16 | 雅培制药有限公司 | 抗病毒化合物 |
MX2011010905A (es) | 2009-04-15 | 2011-11-01 | Abbott Lab | Compuestos antivirales. |
EP2337781B1 (en) | 2009-06-11 | 2014-07-23 | AbbVie Bahamas Ltd. | Anti-viral compounds to treat hcv infection |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
AU2010274001A1 (en) * | 2009-07-16 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of Flavivirus infections |
SG178952A1 (en) | 2009-09-04 | 2012-04-27 | Glaxosmithkline Llc | Chemical compounds |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
CN103709181B (zh) * | 2012-09-29 | 2016-06-22 | 昆山维信诺显示技术有限公司 | 含咪唑并[1,2-a]吡啶基团的稠环芳烃衍生物及其应用 |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
AU2019222644B2 (en) | 2018-02-13 | 2021-04-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
JP7105359B2 (ja) | 2018-07-13 | 2022-07-22 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
JP2023529867A (ja) | 2020-06-05 | 2023-07-12 | キネート バイオファーマ インク. | 線維芽細胞増殖因子受容体キナーゼの阻害剤 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL194025B1 (pl) | 1996-10-18 | 2007-04-30 | Vertex Pharma | Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych |
CA2294049A1 (en) | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptides |
DE69827956T2 (de) | 1997-08-11 | 2005-04-14 | Boehringer Ingelheim (Canada) Ltd., Laval | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
DE69925918T2 (de) | 1998-07-27 | 2006-05-11 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Diketosäure-derivate als hemmstoffe von polymerasen |
AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
TR200103147T1 (tr) | 1999-12-27 | 2002-06-21 | Japan Tobacco Inc. | Kaynaşık halkalı bileşikler ve bunların ilaç olarak kullanımı. |
AU2001261377A1 (en) | 2000-05-10 | 2001-11-20 | Smith Kline Beecham Corporation | Novel anti-infectives |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
BR0115447A (pt) | 2000-11-20 | 2005-10-18 | Bristol Myers Squibb Co | Inibidores de tripeptìdeo de hepatite c |
EP1539188B1 (en) | 2001-01-22 | 2015-01-07 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
WO2002069903A2 (en) | 2001-03-06 | 2002-09-12 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
EP1256628A3 (en) | 2001-05-10 | 2003-03-19 | Agouron Pharmaceuticals, Inc. | Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof |
AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
KR100900304B1 (ko) | 2001-06-11 | 2009-06-02 | 바이로켐 파마 인코포레이티드 | 플라비 바이러스 감염용 항바이러스제로서의 티오펜 유도체 |
CA2449999C (en) | 2001-06-11 | 2012-07-31 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
AU2002337765A1 (en) | 2001-09-26 | 2003-04-07 | Bristol-Myers Squibb Company | Compounds useful for treating hepatitus c virus |
AU2002348414B2 (en) | 2001-10-24 | 2009-10-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system |
SG159385A1 (en) | 2002-04-11 | 2010-03-30 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease |
CN100453553C (zh) | 2003-04-11 | 2009-01-21 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂 |
TW200510391A (en) | 2003-04-11 | 2005-03-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
EP1646642A2 (en) | 2003-07-18 | 2006-04-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
MY148123A (en) | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
JP4685775B2 (ja) | 2003-09-18 | 2011-05-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、とりわけhcvns3−ns4aプロテアーゼの阻害剤 |
EP1711515A2 (en) | 2004-02-04 | 2006-10-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
JP2008506702A (ja) | 2004-07-14 | 2008-03-06 | ピーティーシー セラピューティクス,インコーポレーテッド | C型肝炎を治療するための方法 |
NZ554351A (en) | 2004-10-01 | 2010-02-26 | Vertex Pharma | HCV NS3-NS4A protease inhibition using VX-950, also known as telaprevir |
US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2097405A2 (en) * | 2006-11-21 | 2009-09-09 | Smithkline Beecham Corporation | Anti-viral compounds |
EP2393359A4 (en) * | 2009-02-09 | 2012-10-03 | Enanta Pharm Inc | COMPOUND DIBENZIMIDAZOLE DERIVATIVES |
US8188132B2 (en) * | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
MX2011008982A (es) * | 2009-02-27 | 2011-09-15 | Enata Pharmaceuticals Inc | Inhibidores del virus de la hepatitis c. |
US8101643B2 (en) * | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
AU2010274001A1 (en) * | 2009-07-16 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of Flavivirus infections |
WO2011050146A1 (en) * | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Chemical compounds |
US20110274648A1 (en) * | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110269956A1 (en) * | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
-
2011
- 2011-03-24 WO PCT/US2011/029833 patent/WO2011119858A1/en active Application Filing
- 2011-03-24 EP EP11715104A patent/EP2550262A1/en not_active Withdrawn
- 2011-03-24 TW TW100110269A patent/TW201139438A/zh unknown
- 2011-03-28 AR ARP110101005A patent/AR080811A1/es unknown
-
2012
- 2012-09-24 US US13/625,151 patent/US20130085150A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2011119858A1 (en) | 2011-09-29 |
TW201139438A (en) | 2011-11-16 |
EP2550262A1 (en) | 2013-01-30 |
US20130085150A1 (en) | 2013-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR080811A1 (es) | Analogos para el tratamiento o prevencion de infecciones por flavivirus | |
AR080726A1 (es) | Analogos para el tratamiento o prevencion de infecciones por flavivirus y composiciones farmaceuticas que los comprenden | |
AR080725A1 (es) | Analogos para el tratamiento o prevencion de infecciones por flavivirus y composiciones farmaceuticas que las comprenden | |
AR081061A1 (es) | Agentes heterociclicos antivirales utiles para el tratamiento de infecciones por flavovirus, en particular vhc, y composiciones farmaceuticas que los contienen | |
AR121661A2 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
AR101106A1 (es) | Inhibidores de tirosina quinasa de bruton | |
AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
AR103574A1 (es) | Compuestos tricíclicos y usos de lo mismos en medicina | |
DOP2014000121A (es) | Derivados de betulina | |
IN2014MN02652A (es) | ||
RS54208B1 (en) | NEMATOCIDE SULFONAMIDES | |
SI2997033T1 (en) | FUZYCLE TRICYCLE HETEROCYCLIC COMPOUNDS AS HIV INTEGRATED INHIBITORS | |
IN2014MN02657A (es) | ||
AR083058A1 (es) | Compuestos de estructura de imidazotriazinona | |
AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
AR081830A1 (es) | Activadores de guanilato ciclasa soluble, composiciones farmaceuticas que los comprenden y sus usos | |
AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
AR048939A1 (es) | Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios. | |
AR089182A1 (es) | Derivados de aminopirimidina como moduladores de lrrk2 | |
EA201690247A1 (ru) | Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения | |
AR085285A1 (es) | Metodos para tratar enfermedades de la retina | |
AR064318A1 (es) | Compuesto y composicion derivada de aril sulfamida, uso del compuesto y proceso para la preparacion del compuesto | |
AR081252A1 (es) | Compuestos para el tratamiento del sindrome metabolico | |
AR081691A1 (es) | Derivados de tiofeno, metodos para su preparacion y su uso en el tratamiento o la prevencion de infecciones por flavivirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |